Diphtheria Toxoid
drugOn this page
Also known as Diphtheria toxoid component of hexacimaDiphtheria toxoid component of hexavacDiphtheria toxoid component of hexyonDiphtheria toxoid component of primavaxDiphtheria toxoid component of vaxelis
Summary
Diphtheria Toxoid (CHEMBL2109121) is an approved vaccine component (ATC J07AF01); indicated across 10 conditions including tetanus and dengue hemorrhagic fever.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Vaccine component
- ATC class: J07AF01
- Indications: 10 conditions
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109121 |
| Name | Diphtheria Toxoid |
| Type | Vaccine component |
| Max phase | 4 |
| ATC | J07AF01 |
Also known as: Diphtheria toxoid, Diphtheria toxoid component of hexacima, Diphtheria toxoid component of hexavac, Diphtheria toxoid component of hexyon, Diphtheria toxoid component of primavax, Diphtheria toxoid component of vaxelis, DIPHTHERIA TOXOID
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
10 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| tetanus | 4 | MONDO:0005526 | EFO:0005593 |
| Dengue hemorrhagic fever | 3 | MONDO:0005358 | EFO:0004227 |
| meningococcal infection | 3 | MONDO:0005373 | EFO:0004249 |
| alopecia areata | 3 | MONDO:0005340 | EFO:0004192 |
| dengue disease | 3 | MONDO:0005502 | EFO:0005547 |
| meningococcal meningitis | 3 | MONDO:0018059 | EFO:1001040 |
| B-cell chronic lymphocytic leukemia | 2 | MONDO:0004948 | EFO:0000095 |
| glioblastoma | 2 | MONDO:0018177 | EFO:0000519 |
| brain cancer | 1 | MONDO:0001657 | MONDO:0001657 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 2 |
| PHASE2 | 2 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03180034 | PHASE4 | ACTIVE_NOT_RECRUITING | Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study |
| NCT05237947 | PHASE4 | ACTIVE_NOT_RECRUITING | Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial |
| NCT06639074 | PHASE2 | RECRUITING | Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial |
| NCT02518555 | PHASE2 | COMPLETED | Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| NCT00258882 | Not specified | COMPLETED | Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).